Newsroom
The Chemical Daily: Taiwan Special Feature | Interview with TBMC CEO David Chang
Taiwan Bio-Manufacturing Corporation (TBMC), a CDMO focused on advanced therapeutics, is currently building a GMP-compliant manufacturing facility in the Hsinchu Biomedical Science Park…
TBMC Announces PharmaEssentia’s Investment in Its Series A+ Financing Round
Taiwan Bio-Manufacturing Corporation (TBMC) hereby announces that its Series A+ financing round has secured mid- to long-term investment support from PharmaEssentia Corporation(TWSE:6446), with a total investment amount of up to USD 30 million.
TBMC Expands CRDMO Business with Focus on Four Novel Modalities
Taiwan Bio-Manufacturing Corporation (TBMC) specializes in novel drug modalities, including mRNA vaccines, mRNA therapeutics, and cell and gene therapies. The company is actively advancing its CRDMO services…
TBMC Unveils World-Class CRDMO Vision at BIO Asia–Taiwan 2025
BIO Asia–Taiwan 2025, Taiwan’s well-known biotech exhibition, is taking place from July 24 to 26. Today (July 25), Taiwan Bio-Manufacturing Corporation (TBMC) is hosting a media gathering at its booth to unveil its vision of “Being a World-Class Bio-Manufacturing CRDMO.”
TBMC Breaks Ground on Taiwan’s First GMP Facility for Nucleic Acid Medicines
Taiwan Bio-Manufacturing Corporation (TBMC) held a groundbreaking ceremony today (26th) at Hsinchu Biomedical Science Park, officially initiating the construction of Taiwan’s first GMP manufacturing base for mRNA nucleic acid medicines and vaccines…
CBC and TBMC Announce Strategic Partnership and Signed a Memorandum of Agreement for collaboration of Bioprocess service expansion in Japan
Taiwan Bio-Manufacturing Corporation (Headquarters: Taipei, Taiwan; CEO: David Chang; hereinafter referred to as “TBMC”) has announced that CBC will invest Taiwan Bio-Manufacturing Corporation (Headquarters: Taipei, Taiwan; CEO: David Chang…
